Rosetta Genomics Announces Publication of Data Correlating miR-150 to Atrial Fibrillation in Patients With Chronic Systolic H...
March 03 2014 - 9:15AM
Marketwired
Rosetta Genomics Announces Publication of Data Correlating miR-150
to Atrial Fibrillation in Patients With Chronic Systolic Heart
Failure
Study Demonstrating microRNAs to Be Good Biomarkers for Heart
Failure Complements Earlier Rosetta Published Study; Rosetta
Advancing a microRNA-Based Assay in Heart Failure
PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - Mar 3, 2014) -
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular diagnostics, announces data
from a study of the Company's microRNA technology was published
online in the American Journal of Cardiology in an article
entitled, "Relation of Reduced Expression of MiR-150 in Platelets
to Atrial Fibrillation in Patients With Chronic Systolic Heart
Failure." The abstract and full article can be accessed at
http://www.ncbi.nlm.nih.gov/pubmed/24462065.
miRNAs play an essential role in a variety of cardiovascular
pathologies including hypertrophy, fibrosis, arrhythmia, ischemia,
atherosclerosis and heart failure (HF).1 The aim of this study
was to evaluate the potential association of miRNAs in platelets
with atrial fibrillation (AF) in patients with chronic systolic
HF.
In the study, miRNA expression was measured in platelets and
serum samples of 41 HF patients with and without AF and 35 controls
who were age and gender matched to the HF group and had no known
coronary, valvular, paroxysmal or persistent cardiac arrhythmia or
myocardial disease.
The results showed that miR-150 expression was 3.2-fold lower in
platelets of HF patients with AF relative to HF patients without
AF. A similar effect was seen in serum samples from the same
patients, in which miR-150 levels were 1.5-fold lower in HF
patients with AF. Furthermore, the serum levels of miR-150 were
correlated to platelet levels of miR-150 in patients with AF.
In a comparison of miRNA expression levels in platelets from
patients with HF and controls, none of the miRNAs, including
miR-150, showed significant differences between the groups showing
that platelet miRNA expression levels are not significantly altered
by HF.
"An increasing body of evidence indicates the important role of
miRNAs in cardiovascular development and physiological function as
well as in the pathogenesis of a wide range of cardiac diseases
including HF. In addition, miRNAs are present in the circulation in
a stable form and can therefore serve as novel diagnostic markers,"
stated Dganit Bar, Ph.D., Chief Scientific Officer of Rosetta
Genomics.
"Atrial fibrillation is associated with poor prognosis in
patients with heart failure. This study demonstrated a clear and
significant association between both lower circulating and lower
platelet levels of miR-150 levels with atrial fibrillation in
chronic systolic heart failure," noted Kenneth A. Berlin, President
and Chief Executive Officer of Rosetta Genomics. "We are encouraged
by the publication of these important data, which, along with our
earlier study published in the European Journal of Heart Failure in
2012, support our continued research efforts in the area of
blood-based microRNA biomarkers in order to advance new assays for
the early diagnosis and refined risk stratification of heart
failure patients. We plan to perform additional studies aimed at
further examining the expression of identified miRNA biomarkers in
various blood fractions and anticipate launching a new assay
related to this area in 2017."
About Rosetta Cancer Testing Services Rosetta Cancer Tests are a
series of microRNA-based diagnostic testing services offered by
Rosetta Genomics. The Rosetta Cancer Origin Test™ can accurately
identify the primary tumor type in primary and metastatic cancer
including cancer of unknown or uncertain primary (CUP). Rosetta
Mesothelioma Test™ diagnoses mesothelioma, a cancer connected to
asbestos exposure. The Rosetta Lung Cancer Test™ accurately
identifies the four main subtypes of lung cancer using small
amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately
classifies the four most common kidney tumors: clear cell renal
cell carcinoma (RCC), papillary RCC, chromophobe RCC and
oncocytoma. Rosetta's assays are designed to provide objective
diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment. In the U.S.
alone, Rosetta Genomics estimates that 200,000 patients a year may
benefit from the Rosetta Cancer Origin Test™, 60,000 from the
Rosetta Mesothelioma Test™, 65,000 from the Rosetta Kidney Cancer
Test™ and 226,000 patients from the Rosetta Lung Cancer Test™. The
Company's assays are offered directly by Rosetta Genomics in the
U.S., and through distributors around the world. For more
information, please visit www.rosettagenomics.com. Parties
interested in ordering the test can contact Rosetta Genomics at
(215) 382-9000 ext. 309.
About Rosetta Genomics Rosetta develops and commercializes a
full range of microRNA-based molecular diagnostics. Founded in
2000, Rosetta's integrative research platform combining
bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human
microRNAs. Building on its strong patent position and proprietary
platform technologies, Rosetta is working on the application of
these technologies in the development and commercialization of a
full range of microRNA-based diagnostic tools. Rosetta's cancer
testing services are commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. Frost
& Sullivan recognized Rosetta Genomics with the 2012 North
American Next Generation Diagnostics Entrepreneurial Company of the
Year Award.
Forward-Looking Statement Disclaimer Various statements in this
release concerning Rosetta's future expectations, plans and
prospects, including without limitation, Rosetta performing
additional studies aimed at further examining the expression of
identified miRNA biomarkers in various blood fractions, the role of
miRNAs in cardiovascular development and physiological function as
well as in the pathogenesis of a wide range of cardiac diseases
including HF, the possibility of Rosetta launching new assays,
including assays related to the field of heart failure, as well as
the timeline for launching new assays, constitute forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including
those risks more fully discussed in the "Risk Factors" section of
Rosetta's Annual Report on Form 20-F for the year ended December
31, 2012 as filed with the SEC. In addition, any forward-looking
statements represent Rosetta's views only as of the date of this
release and should not be relied upon as representing its views as
of any subsequent date. Rosetta does not assume any obligation to
update any forward-looking statements unless required by law.
1 Papageorgiou N, Tousoulis D, Androulakis E, Siasos G,
Briasoulis A, Vogiatzi G, Kampoli AM, Tsiamis E, Tentolouris C,
Stefanadis C. The role of microRNAs in cardiovascular disease. Curr
Med Chem 2012;19:2605e2610.
Company Contact: Rosetta Genomics Ken Berlin President & CEO
(609) 419-9003 investors@rosettagenomics.com Investor Contacts: LHA
Anne Marie Fields (212) 838-3777 afields@lhai.com or Bruce Voss
(310) 691-7100 bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Sep 2023 to Sep 2024